News about PCV-2

UK Trial Shows Reduced Mortality in Vaccinated Pigs

2009-05-28

UK - Boehringer Ingelheim are a company dedicated to innovation in swine health and were the first company to launch a PCV2 vaccine for piglets, Ingelvac CircoFLEX, to provide early onset of immunity (from 4 weeks) with protection through to slaughter.

With over 150 million doses sold worldwide to date, they can truly boast that its excellent efficacy has been proven by experience - and in the many different production systems practised around the world.

In a major UK trial, for example, vaccinated pigs showed markedly reduced mortality, lower incidence of PDNS, fewer poor pigs, higher average daily weight gain and a 6.8 kg greater finishing weight than unvaccinated controls. Many UK farmers have had the opportunity to see for themselves the benefits achieved by the introduction of an Ingelvac CircoFLEX vaccination programme on their unit under the BPEX PCV2 Research Project. Not only are the benefits seen in terms of a dramatic reduction in mortality but particularly helpful is the dramatic improvement in uniformity and reduction of tail end pigs.

In addition to Ingelvac CircoFLEX®, Enterisol Ileitis, their unique oral vaccine against porcine ileitis, Ingelvac M hyo and Ingelvac PRRS KV make up their swine vaccine range. With PCV2 piglet vaccination along with M hyo vaccination likely to become the industry standard and their commitment to the rest of their product range, Boehringer Ingelheim Vetmedica are committed to playing a prominent part in the industry for many years to come and are pleased to sponsor the British Pig Health Scheme.